{
 "topic": "Chronic Kidney Disease",
 "slug": "chronic-kidney-disease",
 "category_id": 15127,
 "summary": "The NKF-KDOQI/KDIGO definition and staging of pediatric CKD by GFR and albuminuria, its causes by age, and the substantial neurodevelopmental morbidity it carries even at mild severity.",
 "written_by": "claude-sonnet",
 "references": [
  {
   "title": "Kliegman R. Nelson Textbook of Pediatrics 2-Volume Set 22ed 2024",
   "author": null,
   "pages": [
    3282
   ]
  },
  {
   "title": "Cover",
   "author": "Vitalsource Download",
   "pages": [
    6385,
    6905,
    6914
   ]
  },
  {
   "title": "2021_Fleisher_&_Ludwig's_Textbook_of_Pediatric_Emergency_Medicine.epub",
   "author": null,
   "pages": []
  },
  {
   "title": "Netters Pediatrics (Florin \u0422., Ludwig St.)",
   "author": null,
   "pages": [
    423,
    424
   ]
  },
  {
   "title": "Gomella's Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs, Eighth Edition",
   "author": "Tricia Lacy Gomella, Fabien G. Eyal and Fayez Bany-Mohammed",
   "pages": [
    693
   ]
  },
  {
   "title": "Pediatric Clinical Practice Guidelines and Policies",
   "author": "American Academy of Pediatrics (AAP);",
   "pages": [
    1387
   ]
  },
  {
   "title": "Berkowitz's Pediatrics",
   "author": "Berkowitz, Carol D.;",
   "pages": [
    1173
   ]
  },
  {
   "title": "Ghai Essential Pediatrics, 9e (Vinod K Paul, Arvind Bagga)",
   "author": "CamScanner",
   "pages": [
    494
   ]
  }
 ],
 "short": [
  {
   "title": "In short",
   "content": "- CKD (NKF-KDOQI definition) requires either: (1) kidney damage \u22653 months (structural/functional kidney abnormality, with or without decreased GFR, shown by blood/urine abnormalities, imaging abnormalities, or biopsy abnormalities), OR (2) GFR <60 mL/min/1.73m\u00b2 for \u22653 months regardless of other damage markers.\n- Staging by GFR (mL/min/1.73m\u00b2): Stage 1 \u226590 (kidney damage with normal/increased GFR), Stage 2: 60\u201389 (mild decrease), Stage 3a: 45\u201359, Stage 3b: 30\u201344 (moderate decrease, sometimes reported together as Stage 3: 30\u201359), Stage 4: 15\u201329 (severe decrease), Stage 5: <15 or on dialysis (kidney failure).\n- End-stage kidney disease (ESKD) is an administrative US term for the subset of stage 5 CKD patients treated with dialysis or transplantation \u2014 not a separate clinical stage.\n- 2012 KDIGO guidelines added albuminuria to the staging framework alongside GFR, since mortality, cardiovascular risk, and progression risk are independently influenced by both GFR level and albuminuria.\n- Neonatal CKD incidence is about 1 in 10,000 live births; causes include polycystic kidney disease (autosomal recessive or dominant), obstructive uropathy (e.g., posterior urethral valves), hypoplastic/dysplastic kidney, glomerular disease, cortical necrosis, renal vascular thrombosis, and genetic disorders.\n- CKD is a common late complication of hematopoietic stem cell transplant (HSCT): occurs in 20\u201360% of adult HSCT recipients and up to 62% of pediatric HSCT survivors; proteinuria at day +100 post-transplant can increase 1-year nonrelapse mortality risk up to 6-fold. Causes are multifactorial: pre-transplant chemo/radiation, nephrotoxic drugs (calcineurin inhibitors for GVHD), antimicrobials, sinusoidal obstruction syndrome with hepatorenal syndrome, and septic hypotension.\n- The CKiD (Chronic Kidney Disease in Children) cohort study found roughly 21\u201340% (about a third) of children with even mild-to-moderate CKD have impairment in IQ, academic achievement, and attention regulation, correlating with higher blood pressure and lower GFR; language-specific deficits occur and require hearing to be checked before attributing them to CKD; improvement after transplant is inconsistent.\n- Additional cognitive/growth morbidity in pediatric CKD may stem from low birth weight, seizure disorder, congenital anomalies, or acquired complications like renal osteodystrophy, steroid medication effects, and marked growth impairment.\n- Children may present to the ED with previously undiagnosed CKD and life-threatening electrolyte/acid-base disturbances requiring emergent intervention, sometimes including emergent renal replacement therapy (RRT)."
  }
 ],
 "long": [
  {
   "title": "Definition",
   "content": "Chronic kidney disease (CKD) is defined by NKF-KDOQI criteria as either: (1) kidney damage present for 3 months or longer, defined as structural or functional kidney abnormality (with or without decreased GFR) manifested by abnormalities in blood or urine composition, abnormalities on imaging, or abnormalities on kidney biopsy; or (2) GFR below 60 mL/min/1.73 m\u00b2 for 3 months or longer, with or without other signs of kidney damage. This framework deliberately redefines renal dysfunction as a continuum rather than a discrete binary state, replacing the older terms \"chronic renal failure\" and \"chronic renal insufficiency.\" End-stage kidney disease (ESKD) is a US administrative term describing the subset of stage 5 CKD patients who are being treated with dialysis or kidney transplantation, rather than a distinct clinical stage in its own right."
  },
  {
   "title": "Epidemiology",
   "content": "Neonatal CKD has an incidence of about 1 in 10,000 live births. CKD is also a common late complication after hematopoietic stem cell transplantation, occurring in 20\u201360% of adult transplant recipients and as many as 62% of pediatric HSCT survivors; these patients who progress to ESRD have decreased survival compared with other ESRD patients, and proteinuria detected at day +100 post-transplant can increase the risk of nonrelapse mortality by up to 6-fold within the first year."
  },
  {
   "title": "Etiology",
   "content": "Causes of pediatric CKD vary by age of onset. In neonates, causes include polycystic kidney disease (both autosomal recessive and autosomal dominant forms), obstructive uropathy (e.g., posterior urethral valves), hypoplastic or dysplastic kidneys, glomerular disease, cortical necrosis, renal vascular thrombosis, other genetic disorders, and cases of unknown etiology; a family history of diabetes, urinary tract disease, polycystic kidney disease, or congenital nephrotic syndrome should raise suspicion for CKD rather than acute kidney injury. In HSCT recipients, kidney injury is multifactorial, including pre-transplant or concurrent chemotherapy and radiation exposure, nephrotoxic medications during transplant (particularly calcineurin inhibitors used for graft-versus-host disease prophylaxis and treatment), antimicrobial agents (antibiotics, antivirals, antifungals), sinusoidal obstruction syndrome of the liver leading to hepatorenal syndrome, and sepsis with hypotension; while often acute and reversible with withdrawal of the offending agent, injury can progress to chronic disease in some cases."
  },
  {
   "title": "Diagnostics",
   "content": "Diagnosis requires demonstrating persistence of kidney damage or reduced GFR for at least 3 months \u2014 a single abnormal test is not sufficient. Markers of kidney damage include a decreased GFR below 60 mL/min/1.73 m\u00b2, albuminuria, urine sediment abnormalities, electrolyte disturbances from tubular dysfunction, structural abnormalities on imaging or kidney biopsy, or a history of kidney transplantation. GFR in children is generally estimated from creatinine clearance using the Schwartz equation. Staging (applicable to children older than 2 years) is based on GFR: Stage 1, GFR \u226590 with kidney damage; Stage 2, GFR 60\u201389 with mild damage; Stage 3a, GFR 45\u201359; Stage 3b, GFR 30\u201344 (moderate decrease); Stage 4, GFR 15\u201329 (severe decrease); Stage 5, GFR <15 or on dialysis (kidney failure). The 2012 KDIGO update incorporated albuminuria into this staging system alongside GFR, since the two markers independently and jointly predict mortality, cardiovascular complications, and disease progression risk."
  },
  {
   "title": "Complications",
   "content": "CKD carries substantial neurodevelopmental morbidity even at mild-to-moderate severity: the CKiD cohort study found that roughly a third of affected children (21\u201340%) show impairment in IQ, academic achievement, and attention regulation, with elevated blood pressure and lower GFR associated with lower scores; specific language deficits have also been observed, and hearing impairment should be excluded before attributing these to CKD itself. Improvement after kidney transplantation is inconsistent. Additional morbidity in pediatric CKD can arise from coexisting factors (low birth weight, seizure disorder, congenital anomalies) or from acquired complications of the renal disease itself, including severe renal osteodystrophy, adverse effects of medications (particularly corticosteroids), and marked growth impairment. Children with previously undiagnosed CKD can present acutely with life-threatening electrolyte and acid-base disturbances requiring emergent intervention, including, in some cases, emergent renal replacement therapy."
  }
 ],
 "clinical": [
  {
   "title": "Management approach",
   "content": "Confirm the diagnosis by documenting either kidney damage markers or a GFR below 60 mL/min/1.73 m\u00b2 persisting for at least 3 months \u2014 a single abnormal lab value is not diagnostic of CKD and should prompt repeat testing rather than immediate labeling. Stage the disease by GFR (and, per KDIGO, by albuminuria as well) to guide the intensity of monitoring and anticipate stage-specific complications, since certain manifestations of CKD emerge at predictable GFR thresholds regardless of the underlying cause.\n\nInvestigate etiology systematically: in a neonate or young infant, take a careful family history (diabetes, urinary tract disease, polycystic kidney disease, congenital nephrotic syndrome) since these point toward a chronic rather than acute process, and evaluate for structural causes (obstructive uropathy, dysplastic/hypoplastic kidneys, polycystic kidney disease) with appropriate imaging. In an HSCT survivor, monitor proteinuria proactively (including at day +100 post-transplant) given its strong association with nonrelapse mortality, and review the drug list for nephrotoxic exposures (calcineurin inhibitors, certain antimicrobials) that may be modifiable.\n\nScreen children with CKD \u2014 even mild-to-moderate stages \u2014 for cognitive, academic, and attention difficulties rather than assuming normal neurodevelopment, and check hearing before attributing language deficits to the kidney disease itself. Monitor for and manage renal osteodystrophy and growth impairment, and weigh medication choices (particularly corticosteroid exposure) against their contribution to these complications. If a child presents acutely with previously undiagnosed CKD, prioritize restoring electrolyte and acid-base homeostasis, treat any identifiable underlying cause, and be prepared to initiate emergent renal replacement therapy if life-threatening derangements are present."
  }
 ]
}